RWA Wealth Partners LLC Sells 3,124 Shares of Thermo Fisher Scientific Inc. $TMO

RWA Wealth Partners LLC decreased its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 45.3% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 3,779 shares of the medical research company’s stock after selling 3,124 shares during the period. RWA Wealth Partners LLC’s holdings in Thermo Fisher Scientific were worth $1,880,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of the stock. Revolve Wealth Partners LLC boosted its position in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Port Capital LLC boosted its position in Thermo Fisher Scientific by 1.6% during the fourth quarter. Port Capital LLC now owns 1,385 shares of the medical research company’s stock valued at $721,000 after purchasing an additional 22 shares during the last quarter. Clark Capital Management Group Inc. raised its stake in Thermo Fisher Scientific by 0.5% in the fourth quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company’s stock valued at $2,312,000 after buying an additional 23 shares during the period. Monograph Wealth Advisors LLC raised its stake in Thermo Fisher Scientific by 0.3% in the fourth quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company’s stock valued at $4,507,000 after buying an additional 23 shares during the period. Finally, Intergy Private Wealth LLC raised its stake in Thermo Fisher Scientific by 5.8% in the first quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company’s stock valued at $208,000 after buying an additional 23 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company’s stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $451.82, for a total value of $4,518,200.00. Following the completion of the transaction, the chief executive officer directly owned 115,174 shares of the company’s stock, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock worth $8,345,792 over the last ninety days. Company insiders own 0.33% of the company’s stock.

Analysts Set New Price Targets

Several research firms have issued reports on TMO. Robert W. Baird upped their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a research note on Thursday, July 24th. William Blair initiated coverage on Thermo Fisher Scientific in a research note on Monday. They issued an “outperform” rating on the stock. Raymond James Financial reiterated an “outperform” rating and set a $535.00 target price (up previously from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Argus lowered their target price on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a research note on Tuesday, April 29th. Finally, Royal Bank Of Canada lowered their target price on Thermo Fisher Scientific from $651.00 to $637.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $593.00.

Thermo Fisher Scientific Trading Up 2.1%

Shares of TMO stock opened at $497.9350 on Wednesday. The stock’s fifty day moving average price is $438.09 and its two-hundred day moving average price is $458.53. The company has a market cap of $188.03 billion, a PE ratio of 28.80, a P/E/G ratio of 2.60 and a beta of 0.74. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $627.88. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.50 and a current ratio of 1.93.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts’ consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The firm had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter last year, the business posted $5.37 EPS. The company’s revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.95%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.